Literature DB >> 25517794

Advanced nanocarriers based on heparin and its derivatives for cancer management.

Xiaoye Yang1, Hongliang Du, Jiyong Liu, Guangxi Zhai.   

Abstract

To obtain a satisfying anticancer effect, rationally designed nanocarriers are intensively studied. In this field, heparin and its derivatives have been widely attempted recently as potential component of nanocarriers due to their unique biological and physiochemical features, especially the anticancer activity. This review focuses on state-of-the-art nanocarriers with heparin/heparin derivatives as backbone or coating material. At the beginning, the unique advantages of heparin used in cancer nanotechnology are discussed. After that, different strategies of heparin chemical modification are reviewed, laying the foundation of developing various nanocarriers. Then a systematic summary of diverse nanoparticles with heparin as component is exhibited, involving heparin-drug conjugate, polymeric nanoparticles, nanogels, polyelectrolyte complex nanoparticles, and heparin-coated organic and inorganic nanoparticles. The application of these nanoparticles in various novel cancer therapy (containing targeted therapy, magnetic therapy, photodynamic therapy, and gene therapy) will be highlighted. Finally, future challenges and opportunities of heparin-based biomaterials in cancer nanotechnology are discussed.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25517794     DOI: 10.1021/bm501532e

Source DB:  PubMed          Journal:  Biomacromolecules        ISSN: 1525-7797            Impact factor:   6.988


  14 in total

Review 1.  The role of heparins and nano-heparins as therapeutic tool in breast cancer.

Authors:  Nikos A Afratis; Konstantina Karamanou; Zoi Piperigkou; Demitrios H Vynios; Achilleas D Theocharis
Journal:  Glycoconj J       Date:  2016-10-24       Impact factor: 2.916

2.  An iRGD peptide conjugated heparin nanocarrier for gastric cancer therapy.

Authors:  Shichao Ai; Shuang Zhen; Zhijian Liu; Feng Sun; Xingchen He; Feng Chu; Wenxian Guan; Jianquan Wang
Journal:  RSC Adv       Date:  2018-08-24       Impact factor: 4.036

Review 3.  Glycosaminoglycan-Based Biohybrid Hydrogels: A Sweet and Smart Choice for Multifunctional Biomaterials.

Authors:  Uwe Freudenberg; Yingkai Liang; Kristi L Kiick; Carsten Werner
Journal:  Adv Mater       Date:  2016-07-27       Impact factor: 30.849

Review 4.  Polysaccharide-based nanoparticles for theranostic nanomedicine.

Authors:  M Swierczewska; H S Han; K Kim; J H Park; S Lee
Journal:  Adv Drug Deliv Rev       Date:  2015-11-27       Impact factor: 15.470

5.  In Situ Synthesis of Magnetic Field-Responsive Hemicellulose Hydrogels for Drug Delivery.

Authors:  Weifeng Zhao; Karin Odelius; Ulrica Edlund; Changsheng Zhao; Ann-Christine Albertsson
Journal:  Biomacromolecules       Date:  2015-07-30       Impact factor: 6.988

Review 6.  Heparin: Past, Present, and Future.

Authors:  Eziafa I Oduah; Robert J Linhardt; Susan T Sharfstein
Journal:  Pharmaceuticals (Basel)       Date:  2016-07-04

Review 7.  Smart Carriers and Nanohealers: A Nanomedical Insight on Natural Polymers.

Authors:  Sreejith Raveendran; Ankit K Rochani; Toru Maekawa; D Sakthi Kumar
Journal:  Materials (Basel)       Date:  2017-08-10       Impact factor: 3.623

8.  The AIB1siRNA-loaded hyaluronic acid-assembled PEI/heparin/Ca2+ nanocomplex as a novel therapeutic strategy in lung cancer treatment.

Authors:  Ying Hao; Yongsheng Gao; Yedan Wu; Changshan An
Journal:  Int J Mol Med       Date:  2018-12-03       Impact factor: 4.101

9.  Nanoencapsulation Enhances Anticoagulant Activity of Adenosine and Dipeptide IleTrp.

Authors:  Trung Dinh Nguyen; The Ngoc Nguyen; Trang Thuy Thi Nguyen; Igor A Ivanov; Khoa Cuu Nguyen; Quyen Ngoc Tran; Anh Ngoc Hoang; Yuri N Utkin
Journal:  Nanomaterials (Basel)       Date:  2019-08-23       Impact factor: 5.076

10.  Development of redox-responsive theranostic nanoparticles for near-infrared fluorescence imaging-guided photodynamic/chemotherapy of tumor.

Authors:  Xiaoye Yang; Xiaoqun Shi; Jianbo Ji; Guangxi Zhai
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.